Sharp Therapeutics Corp., a preclinical-stage drug discovery company, developes therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library, binds proteins allosterically, thus stabilizing and activating them; And Mine, a proprietary IP-protected analytics platform, captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.